Skip to content
Open access

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Sep 2026 · Alimentary Pharmacology and Therapeutics · 2 citations · 22 references
Medicine

TL;DR

Upadacitinib was effective and well-tolerated in AT-experienced Crohn's disease, including patients with active EIMs, with induction benefit maintained through 6 months without novel safety signals.

Abstract

Background

AND

Aims

Upadacitinib is an oral selective JAK1 inhibitor approved for moderate-to-severe Crohn's disease (CD), but real-world prospective multicentre data in advanced therapy-experienced (AT-experienced) patients are limited. The UPGRADE-CD study evaluated its effectiveness and safety.

Methods

In this prospective, multicentre, observational study across 38 Italian centres, we enrolled consecutive AT-experienced CD patients initiating upadacitinib. Effectiveness was assessed at weeks 12 and 24, including clinical response (HBI reduction ≥ 3) and remission (HBI ≤ 4), steroid-free counterparts, biomarker normalisation, resolution of extraintestinal manifestations (EIMs) and endoscopic outcomes. Safety was assessed in all patients receiving ≥ 1 dose.

Results

A total of 391 patients were included in the safety analysis and 323 in the efficacy analysis; 48% had failed more than two advanced therapies. Clinical remission reached 51.2% at Week 12 and 54.7% at Week 24 (p = 0.07). Steroid-free clinical response rose from 53.8% to 63.5% (p = 0.09). Active EIMs, present in 39.9% at baseline, resolved completely in 65.7% by Week 24. Higher baseline HBI was the strongest predictor of failure to achieve remission. Discontinuation by Week 24 was 11.3%, mainly from treatment failure (7.2%) and adverse events (3.1%). No major cardiovascular, thromboembolic events or malignancies occurred.

Conclusions

Upadacitinib was effective and well-tolerated in AT-experienced CD, including patients with active EIMs, with induction benefit maintained through 6 months without novel safety signals.

Read PDF

Similar papers

Sep 2026

Efficacy and safety of upadacitinib in anti-TNF-refractory intestinal Behçet's disease: a single-center retrospective study.

OBJECTIVES To evaluate the efficacy and safety of upadacitinib in patients with anti-TNF -refractory intestinal Behçet's disease (BD). METHODS We conducted a single-center retrospective study using data from a maintained BD registry at Peking Union Medical College Hospital between July 2024 and April 2026. Seventeen...

Jing-Wen Wu, Jian-Mei Wang, Xiao-Yin Bai et al. · 0 citations
Open access Sep 2026

Real-world efficacy and safety of upadacitinib in difficult-to-treat Crohn's disease: a 24-week multicenter study from China.

Background/Aims Real-world evidence for upadacitinib use in strictly defined difficult-to-treat Crohn's disease (DTT-CD), particularly in Asian populations, remains limited. Herein, we aimed to evaluate the efficacy and safety of upadacitinib in Chinese patients with DTT-CD. Methods This multicenter, bidirectional co...

Zi-Le Zhang, Shuowen Zhang, Wen-Song Ge et al. · 0 citations
Review Open access Sep 2026

Multicentre, prospective, observational study on the effectiveness and safety of upadacitinib for active perianal fistulising Crohn’s disease in patients with prior anti-tumour necrosis factor failure: a study protocol

Abstract Background Perianal fistulising Crohn’s disease (pfCD) is a debilitating phenotype and remains a therapeutic challenge. Current guidelines recommend anti-tumour necrosis factor agents as first-line therapy for pfCD; however, there is still no consensus on the optimal pharmacological strategy once anti-TNF ther...

Chong Lu, Dong-Bo Xu, K. Qian et al. · 0 citations
Open access Nov 2026

Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis

BACKGROUND Many patients with Crohn’s disease (CD) remain uncontrolled despite multiple biologic therapies. Risankizumab, a selective interleukin-23p19 inhibitor, has shown efficacy in clinical trials, but real-world data in multirefractory CD are still scarce. AIM To evaluate the 12-month effectiveness and safety o...

A. Caballero-Mateos, T. Valdés-Delgado, R. Olmedo Martín et al. · 1 citation
Open access Aug 2026

Efficacy and safety of upadacitinib for Crohn's disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies.

BACKGROUND Upadacitinib is an oral Janus kinase inhibitor approved for the treatment of moderate-to-severe Crohn's disease (CD). This post hoc analysis reports the efficacy and safety of upadacitinib for CD in patients in East Asia enrolled in the phase 3 clinical trials. METHODS In two induction studies (U-EXCEL [NC...

Min-Hu Chen, Xiang Gao, Kenji Watanabe et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.